Skip to search formSkip to main contentSkip to account menu

GSK 2126458

Known as: GSK-2126458, GSK2126458, PI3K Inhibitor GSK2126458 
A small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity. PI3K inhibitor… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Modulation of collagen formation and crosslinking in the Scar-in-a-Jar model
Background: Fibroblasts are responsible for the excessive accumulation of collagens in fibrosis. Here we describe the use of the… 
Review
2016
Review
2016
Repositioning compounds from cancer drug discovery to IPF: PI3K inhibition
Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease that presents with a 5-year survival of 20–30%, hence… 
2016
2016
The effects of anticancer drugs TSA and GSK on spermatogenesis in male mice.
OBJECTIVE The effect of anticancer drugs Trichostation A (TSA) and GSK2126458 (GSK) on genetic recombination of sperm meiosis in… 
2016
2016
Calcineurin inhibitors suppress intestinal cellular respiration
The calcineurin inhibitors, tacrolimus and cyclosporine, are commonly used immunosuppressants, and transplant patients on these… 
2014
2014
Abstract CT205: A phase I dose-escalation study of trametinib (T) in combination with continuous or intermittent GSK2126458 (GSK458) in patients (pts) with advanced solid tumors
Objectives: The primary objectives were to assess safety, tolerability and the maximum tolerated dose (MTD) for the combination… 
2014
2014
Abstract 3951: Dual phosphoinositide 3-kinase/Mammalian target of rapamycin inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma
Purpose Although combined chemo-radiotherapy has provided considerable improvements for nasopharyngeal carcinoma (NPC… 
2014
2014
Evaluation of WO2013117503 and WO2013117504: the use of PI3K inhibitors to treat cough or idiopathic pulmonary fibrosis
Two applications claim the use of the closely related, broad spectrum phosphatidylinositol 3-kinase inhibitors 2,4-difluoro-N-{2… 
2013
2013
Discovery of a Potent and Selective DDR 1 Receptor Tyrosine Kinase Inhibitor
The DDR1 receptor tyrosine kinase is activated by matrix collagens and has been implicated in numerous cellular functions such as… 
2013
2013
319 SYNERGISTIC EFFECT OF COMBINATION OF AZD6244 AND GSK2126458 ON CELL DEATH IN HUMAN PROSTATE CANCER DU145 CELL LINE
2012
2012
Preclinical Development Combinations of BRAF , MEK , and PI 3 K / mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK 2118436 Dabrafenib , Mediated by NRAS or MEK Mutations
Recent results from clinical trials with the BRAF inhibitors GSK2118436 (dabrafenib) and PLX4032 (vemurafenib) have shown… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)